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Cell Differentiation Induced by
Poly(ADP-ribose) Synthetase Inhibitors
Kunihiro Veda, Marek Banasik, Sachiko Nakajima, Rye-Young Yook and Takahiro Kido
We recently found two groups of inhibitors of poly(ADP-ribose) synthetase, i.e. vesnarinones and
heterocyclic amines, to induce differentiation of murine teratocarcinoma EC cells in culture. Cell
morphology changed almost completely in 5 to 7 days after treatment with 70 I-tM benzylvesnarinone or 1
mM PhIP. Analyses of poly(ADP-ribose) synthesis and NAD concentrations in EC cells suggested that
poly(ADP-ribose) might playa role in initiation of cell differentiation.
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Poly(ADP-ribose) is a macromolecule synthesized
from NAD in nuclei of eucaryotic cells (1). Mter 30
years from its discovery, precise biological functions
of poly(ADP-ribose) remain still unclear. In order to
obtain useful tools for in vivo studies, we made an
extensive survey of poly(ADP-ribose) synthetase
inhibitors for years, and found a number of potent
inhibitors (2). Recently we added several more to the
list of inhibitors, among which were vesnarinones
and heterocyclic amines [3]. In this report, we pre-
sent evidence that these new inhibitors are capable of
inducing cell differentiation and that poly(ADP-
ribose) plays a role in this cellular event.
Vesnarinone (Fig. 1) is a therapeutic drug used for
cardiac failure. Its action is reportedly to increase the
intracellular Ca2+ concentration [4]. We found this
compound to inhibit the activity of poly(ADP-ribose)
synthetase. The inhibition was not very strong; 14
and 32% inhibition was observed at 0.1 and 0.5 rnM,
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Figure 1. Chemical structures of vesnarinone (3,4-dihydro-
6[4-(3,4-dimethoxybenzoyl)-1-piperaziny1]-2(lH)-quinoli-
none), Trp-P-l (3-amino-l,4-dimethyl-5H-pyrido[4,3-bJ
indole), and PhIP (2-amino-l-methyl-6-phenylimidazo[4,5-bJ-
pyridine).
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Scope of research
This laboratory was founded in 1994, aiming at the linkage between basic sciences and clinical medicine.
Thus, our research scope encompasses structures / functions of various biomolecules, their abnormalities caus-
ing diseases, and their molecular mechanisms of control useful to therapy. Our current interest is focussed on
pathophysiological roles ofpoly(ADP-riboseJ in carcinogenesis and apoptosis, and of A / f3-amyloid precursor
proteins in Alzheimer's disease. Gene technology and its application to clinical diagnosis are another target
ofour current effort.
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Figure 3. Time course of EC cell differentiation induced by
varying concentrations ofbenzylvesnarinone (6).
These results, together with our previous observa-
tions with other inhibitors of poly(ADP-ribose) syn-
thetase, such as 3-aminobenzamide [7J or 4-hydroxy-
quinazoline [6J, support the view that induction of
teratocarcinoma cell differentiation is a property com-
mon to inhibitors of this enzYme. Thus, poly(ADP-
ribose) appears to participate in cell differentiation at
an early stage of induction.
In addition to EC cells, other malignant cells,
including Friend erythroleukemia cells and HL-60
promyelocytic leukemia cells, have been shown to be
induced to differentiate by poly(ADP-ribose) syn-
thetase inhibitors. These results may suggest a novel
way of chemotherapy, that is, normalizing malignant
cells by induction of differentiation.
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Among heterocyclic amines or pyrolysis products
of various amino acids, Trp-P-1 and Trp-P-2 are the
most potent in mutagenesis and/or carcinogenesis [5J.
We found these y-carbolines to inhibit the poly(ADP-
ribose) synthetase activity. Trp-P-1 was a strong
inhibitor (IC50 = 0.22 rnM), while Trp-P-2 was a
weak inhibitor (IC50 = 2.2mM). In addition to Trp-P-
1 and Trp-P-2, many other heterocyclic amines,
including PhIP that is the most abundant in foods,
proved to be, more or less, inhibitory to poly(ADP-
ribose) synthetase (6).
We recently found that vesnarinones and hetero-
cyclic amines are also capable of inducing differentia-
tion of murine teratocarcinoma EC cells. EC cells are
pluripotent stem cells and differentiate into many cell
types when treated with inducers, including
inhibitors of poly(ADP-ribose) synthetase [1, 6J,
The EC cells grew in small-cell mass, free of con-
tact inhibition, in control culture. When the cells
were cultured for a day or longer in the presence of
vesnarinone, benzylvesnarinone, Trp-P-1, or PhIP,
the cell mass dispersed, and each cell became larger,
flatter and contact-inhibited (Fig. 2). Studies with
varying concentrations of benzylvesnarinone (Fig. 3)
showed that the cells started to change morphology
from the second day, and almost all cells treated with
>50 /-lM of the drug acquired the differentiated cell
shape in a week.
We then analyzed acceptors and extents of
poly(ADP-ribose) synthesis in the course of EC cell
differentiation. Our preliminary data indicated that
the intracellular NAD concentration decreased pre-
cipitously within a day after treatment with an
inducer of differentiation (e.g. all-trans-retinoic acid),
and, at the same time, endogenous poly(ADP-ribose)
synthesis on various proteins including the syn-
thetase itself increased remarkably, whereas the syn-
thetase activity, as assayed in vitro, continued to
decrease throughout the course (6). The transient
activation of the synthetase automodification at an
early stage of differentiation appeared to be relevant
to massive DNA fragmentation and apoptosis induced
by the differentiation inducer.
Figure 2. Phase-contrast photomicrographs of murine tera-
tocarcinoma EC cells cultured (A) with no addition for 5
days or (B) with 1 mM PhIP for 7 days (6).
